NZ considers restrictions
This article was originally published in OTC Bulletin & The Rose Sheet
Medsafe’s Medicines Classification Committee (MCC) is set to discuss whether to further restrict access to modified-release paracetamol products in New Zealand, following a recommendation from the country’s Medicines Adverse Reactions Committee (MARC).
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
Brands unfairly attacked by powerful influencers could raise the subject with the US Federal Trade Commission, which is asking for comments on its “Endorsement Guides."